Firefly Neuroscience, Inc. (AIFF) Stock Price & Analysis
Firefly Neuroscience, Inc. (AIFF) rose 0.62% to USD 1.61 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.
AIFF last closed at USD 1.6; the session ranged USD 1.52–1.68 on volume of 185,121 shares. Market capitalization is $25.07M, with a 52-week range of USD 0.62–3.77 (NCM). Source: Nexqual, June 10, 2026 at 02:21 UTC.
Key Statistics (as of June 10, 2026 at 02:21 UTC)
| Price | USD 1.61 |
|---|---|
| Change | ▲ 0.62% (up) |
| Previous Close | USD 1.6 |
| Open | USD 1.62 |
| Day Range | USD 1.52 – 1.68 |
| 52-Week Range | USD 0.62 – 3.77 |
| Volume | 185,121 shares |
| Market Cap | $25.07M |
| Exchange | NCM |
Technical Analysis (AIFF)
Nexqual's technical model rates AIFF "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.01 (neutral) |
| vs SMA50 | Below (USD 1.86) |
| MACD | -0.07 (negative) |
Analyst Ratings (AIFF)
Wall Street analysts rate AIFF "None", per Nexqual as of June 10, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|
Earnings (AIFF)
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Financials & Fundamentals (AIFF)
| Total Revenue | $1.58M |
|---|---|
| Revenue Growth (YoY) | +1027.90% |
| Gross Margin | +51.96% |
| Operating Margin | -414.43% |
| Profit Margin | +0.00% |
| ROE | -131.44% |
| Current Ratio | 1.82 |
| Total Cash | $3.13M |
| Total Debt | $0 |
| Free Cash Flow | $-9.79M |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Financial Health Score (AIFF)
Nexqual rates Firefly Neuroscience, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -131%, ROA -45.7% |
Ownership (AIFF)
| Insider Ownership | +28.00% |
|---|---|
| Institutional Ownership | +7.88% |
| Shares Outstanding | 15.57M |
| Float | 13.58M |
| Short % of Float | +5.53% |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
Leadership (AIFF)
Firefly Neuroscience, Inc. is led by Greg Lipschitz (age 36), CEO & Director, per Nexqual as of June 10, 2026 at 02:21 UTC.
| CEO & Director | Greg Lipschitz (age 36) |
|---|---|
| President, COO & Director | David DeCaprio (age 52) |
| CFO & Company Secretary | Paul Krzywicki CPA, CGA (age 40) |
| Chief Technology Officer | Gil Issachar (age 42) |
Major Backers & Investors (AIFF)
Notable institutional backers of Firefly Neuroscience, Inc. include Jane Street Group, LLC, Schonfeld Strategic Advisors Llc, Fidelity, according to Nexqual as of June 10, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 1.16% |
| Schonfeld Strategic Advisors Llc | 1.14% |
| Fidelity | 0.86% |
| UBS Group AG | 0.85% |
| Scientech Research LLC | 0.26% |
| Xtx Topco Ltd | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.77% |
| BlackRock | 1.29% |
| Geode Capital | 1% |
| State Street | 0.3% |
Source: Nexqual, June 10, 2026 at 02:21 UTC.
From Firefly Neuroscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America.
- The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JTAI | Jet.AI Inc. | USD 7.81 | ▲ 2.76% |
| TNON | Tenon Medical, Inc. | USD 0.62 | ▲ 2.12% |
| ATPC | Agape ATP Corporation | USD 3.12 | ▲ 4.7% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| SOBR | SOBR Safe, Inc. | USD 0.75 | ▼ 26.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.